BACKGROUND: Prior studies describing the treatment of symptomatic @entity626 with injections of bone marrow concentrate have provided encouraging results. The relationship between the cellular dose contained within the bone marrow concentrate and efficacy of the treatment, however, is unclear. In the present study we describe clinical outcomes for symptomatic @entity626 in relation to higher and lower cell concentrations contained within a bone marrow concentrate treatment protocol. METHODS: Data from an ongoing @entity1 registry was culled to identify 373 @entity1 that received bone marrow concentrate injections for the treatment of 424 @entity2720 . The clinical scales for these @entity1 were assessed at baseline and then tracked post-procedure at 1, 3, 6 and 12  months, and annually thereafter. Tracked outcomes included the numeric @entity158 scale; a lower extremity functional questionnaire; an International Knee Documentation Committee scale; and a subjective improvement rating scale. Using @entity158 and functional outcome measures, a receiver operating characteristic analysis was used to define an optimal clinical outcome threshold at which bone marrow nucleated cell count could be divided into either a lower or higher cell count group within a treatment protocol. RESULTS: The lower and higher cell count groups were defined using a threshold of 4   *   10(8) cells. There were 224 and 185 knee joints treated in the lower ( <=4   *   10(8)) and higher (>4   *   10(8)) cell count groups respectively. Most joints were diagnosed with early stage @entity626 . Both the lower and higher cell count groups demonstrated significant positive results with the treatment for all of the @entity158 and functional metrics. The higher cell count group reported lower post treatment numeric @entity158 scale values, in comparison with the lower cell count group (1.6 vs. 3.2; P   <   0.001). No significant differences were detected for the other metrics, however. CONCLUSIONS: Improved function and reduced @entity158 was observed in @entity1 treated with a bone marrow concentrate protocol regardless of cellular dose; however, @entity1 receiving a higher concentration of cells reported a @entity158 outcome in comparison with the lower dose group. These preliminary findings suggest that cell dose may be an important factor governing clinical outcomes in autologous bone marrow concentrate treatment of @entity626 . Further studies using a larger @entity1 population may help elucidate these findings.

A dose response analysis of a specific bone marrow concentrate treatment protocol for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis'] @entity2720 :: ('MESH:D007592', 'Disease') :: ['osteoarthritic knee joints'] @entity158 :: ('MESH:D010146', 'Disease') :: ['better pain', 'pain']
@entity626 :: (MESH:D020370,Disease) :: ['knee osteoarthritis']
